GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Retained Earnings

Revelation Biosciences (FRA:56U0) Retained Earnings : €-25.90 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Revelation Biosciences's retained earnings for the quarter that ended in Mar. 2024 was €-25.90 Mil.

Revelation Biosciences's quarterly retained earnings declined from Sep. 2023 (€-21.80 Mil) to Dec. 2023 (€-23.35 Mil) and declined from Dec. 2023 (€-23.35 Mil) to Mar. 2024 (€-25.90 Mil).

Revelation Biosciences's annual retained earnings declined from Dec. 2021 (€-12.85 Mil) to Dec. 2022 (€-23.93 Mil) but then increased from Dec. 2022 (€-23.93 Mil) to Dec. 2023 (€-23.35 Mil).


Revelation Biosciences Retained Earnings Historical Data

The historical data trend for Revelation Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Retained Earnings Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-2.08 -12.85 -23.93 -23.35

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.92 -19.05 -21.80 -23.35 -25.90

Revelation Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Revelation Biosciences  (FRA:56U0) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines